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K e y  M e s s a g e s 
1. Probiotic lactic acid bacteria were identified 
to have antifungal properties against Candida 
albicans. 
2. The cell-free supernatant of the lactic acid bacteria 
was successfully fractionated and purified using 
fast performance liquid chromatography. 
3. Eight of the 41 fractions containing the antifungal 
components exhibited a growth inhibitory effect 
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Introduction
Candida is a commensal fungus that inhabits 
various niches of the human body and can cause 
infection under certain circumstances, ranging 
from superficial mucous membrane infection to 
systemic disease with high mortality.1 Rising drug 
resistance and undesirable side effects of currently 
available antifungal agents have prompted research 
of alternative therapeutic strategies.2 Probiotics are 
live microorganisms that confer health benefits on 
the host when administered in adequate amounts 
in food or as a dietary supplement, according to 
the Food Agricultural Organization/World Health 
Organization. Probiotics, such as lactic acid bacteria 
(LAB), are well-recognised for their health benefits 
and have been shown to improve various medical 
conditions, including gastrointestinal disorders, 
cancer, and infectious disease.3 Probiotic-containing 
products can reduce Candida infection such as oral 
candidiasis and vulvovagional candidiasis.4 Probiotic 
products have preferable properties as antifungal 
agents for control of Candida infection, because 
they are natural, effective, and safe. 
 In a preliminary study, we found that LAB 
had antifungal properties. Subsequent experiments 
demonstrated that culture supernatant of LAB 
inhibited the hyphal formation of C albicans in a 
dose-dependent manner, and exhibited fungicidal 
acidity at slightly higher concentrations. LAB 
supernatant was effective in preventing C albicans 
infection in vitro. The present study aimed to 
identify the inhibitory antifungal molecules in the 
LAB supernatant using standard methodology. 
Methods
This study was conducted from October 2012 to 
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Preparation of cell-free supernatant
Lactobacillus species were cultured in Man 
Rogosa Sharpe broth (Difco Laboratories, USA) 
anaerobically at 37°C to the stationary phase. 
Cultures were centrifuged at 9500 × g for 15 min 
and filter-sterilised through a 0.45 μm pore filter 
(Advantec MFS, Japan). The cell-free culture filtrate 
was then used for downstream experiments.
Fractionation and purification of LAB 
supernatant
Proteins of the culture supernatant were purified 
using standard methodology. In brief, proteins in 
the cell-free supernatant were precipitated with 
ammonium sulfate, dissolved in sodium phosphate 
buffer and desalted by overnight dialysis in sodium 
phosphate buffer at 4°C. The mixture of proteins 
was then fractionated in a DEAE Sepharose 
Fast Flow column (HiPrep 16/10 DEAE-FF, GE 
Healthcare) mounted in a fast performance liquid 
chromatography (FPLC) system (Akta purifier, GE 
Healthcare). Activity was eluted at a flow rate of 1 
mL/min using a running buffer of 0.05M Tris (pH 7.5) 
and an elution buffer of 0.05M Tris (pH 7.5) and 2M 
NaCl. A gradient of NaCl was applied linearly from 0 
to 40% (elution buffer). A total of 41 fractions (5 mL 
each) were collected. The total protein concentration 
of each sample was measured using a 2D Quant kit 
(GE Healthcare).
Antifungal activity of the fractions
All fractions were measured for their antifungal 
activity against C albicans using a broth microdilution 
assay in a time-dependent manner. Inocula from 
RESEARCH FUND FOR THE CONTROL OF INFECTIOUS DISEASES
against C albicans. 
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24-hour C albicans cultures were harvested and 
suspended in RPMI 1640 medium with turbidity 
equivalent to McFarland standard 0.5 (1×106 cells/
mL) and then diluted to approximately 0.5×103 to 
2.5×103 cells/mL. The test was performed in pre-
sterilised, flat-bottom 96-well polystyrene plates 
(Iwaki, Japan), with each well filled with 0.1 mL of C 
albicans suspension and 0.1 mL of the fraction. The 
plates were then incubated at 37°C. The inhibitory 
activity of the fractions was recorded by visual 
observations of growth inhibition after 24, 48, and 72 
hours. To verify the results, at the end of the 72-hour 
incubation, aliquots of broth culture were plated 
on the Sabouraud Dextrose Agar and the number 
of colonies was recorded. Fractions with significant 
antifungal activity as shown in the aforementioned 
assay were used for downstream proteomic studies 
to identify the antifungal protein components.
Results
A total of 41 fractions were collected from the FPLC 
purification of the cell-free LAB supernatant. The 
antifungal activity of these fractions is shown in 
the Table. Interestingly, eight of the 41 fractions 
TABLE.  Antifungal activity of the fractions of supernatants 
derived from lactic acid bacteria*
Fraction Time-interval
24 h 48 h 72 h
A1 × × ×
A2 × × ×
A3 × × ×
A4 × × ×
A5 × × ×
A6 × × ×
A7 × × ×
A8 100% 100% 50%
A9 100% 50% ×
A10 100% 100% 50%
A11 × × ×
A12 100% × ×
B1 × × ×
B2 × × ×
B3 × × ×
B4 × × ×
B5 × × ×
B6 100% 50% 50%
B7 100% 50% 50%
B8 100% 100% 100%
B9 100% 100% 100%
B10 × × ×
B11 × × ×
B12 × × ×
C1 × × ×
C2 × × ×
C3 × × ×
C4 × × ×
C5 × × ×
C6 × × ×
C7 × × ×
C8 × × ×
C9 × × ×
C10 × × ×
C11 × × ×
C12 × × ×
D8 × × ×
D9 × × ×
D10 × × ×
D11 × × ×
D12 × × ×
* Complete (100%), partial (50%), or no (x) inhibition of 
growth was recorded for each fraction at each time point. 
Eight of the fractions displayed an inhibitory effect against 
Candida albicans. Four of them exhibited a complete 
inhibitory effect (100%) for 48 hours or more
FIG.  Growth inhibitory effect of each fraction was further evaluated by plating 
on Sabouraud Dextrose Agar and counting of the colony forming units (CFUs): 
the number of CFUs in Fractions B7 and B8 was significantly lower than that in 
controls, with 50% and 100% of the growth inhibitory effect against Candida albicans, 
respectively.
Control
Control
Fraction B7
Fraction B8
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displayed a growth inhibitory effect against C 
albicans. Among these eight fractions, four (A8, A10, 
B8, and B9) exhibited a complete growth inhibitory 
effect (100%) in the broth microdilution assay when 
incubated with C albicans for 48 hours or more. This 
finding indicated that the antifungal components 
of the supernatant were successfully fractionated. 
The growth inhibitory effect of these fractions was 
further confirmed by plating on Sabouraud Dextrose 
Agar and counting of the colony forming units (Fig). 
These fractions were selected for further protein 
identification using liquid chromatography-mass 
spectrometry.
Discussion
Fungal infections, of which candidiasis is the most 
common form, have become a significant problem in 
the clinical setting worldwide, due to an increase in 
immunocompromised populations. In this study, we 
successfully identified LAB strains with antifungal 
activity against C albicans. The antifungal compounds 
of LAB are complex, and their isolation and 
purification from LAB are difficult.5 Despite this, we 
successfully established a protocol for fractionation 
using FPLC, and isolated the working fractions from 
the probiotic supernatant that exhibited a growth 
inhibitory effect against C albicans. We are working 
on identification of the antifungal components in the 
selected fractions using a proteomics approach. 
Conclusions
Candidiasis places a huge burden on public health, 
especially in immunocompromised populations. 
Prophylactic antifungal treatment is associated 
with undesirable side effects. Probiotic products, 
such as LAB, have been proven to be effective and 
safe to prevent and treat candidiasis. Therefore, it 
is important to identify appropriate probiotics and 
associated products. We successfully fractionated 
and purified the cell-free supernatant of LAB 
with antifungal activity using fast performance 
liquid chromatography, and eight of the 41 
fractions exhibited antifungal effects in the broth 
microdilution assay against C albicans. Our findings 
facilitate further investigation of the molecular 
mechanisms of the antifungal activity of LAB.
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